Resonance Health LtdASX: RHT

Investor Presentation Liver Fibrosis Device & Capital Raise

· Issued by Resonance Health Ltd via ASX

Filed with ASX · · 29 pages · English

Summary by 6ix AI

This filing is an investor presentation by Resonance Health Ltd regarding their non-invasive MRI liver fibrosis device and a capital raise. It outlines a placement to raise funds for three growth programs, emphasizing the company's profitable and cash-generative base. The presentation includes preliminary results from a clinical study on liver fibrosis, highlighting the device's investigational status and the need for further verification. Resonance Health aims to leverage structural market tailwinds to enhance their growth trajectory in the healthcare technology sector.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/investor-presentation-liver-fibrosis-device-and-capital-raise

Release

NON-INVASIVE MRI LIVER FIBROSIS DEVICE PRELIMINARY EPOC STUDY RESULTS & CAPITAL RAISING PRESENTATION | OCTOBER 2026 Funding three growth programmes from a profitable, cash-generative base Andrew Harrison | MD & CEO Benjamin Carruthers | CFO Resonance Health Ltd (ASX:RHT) CONFIDENTIAL - NOT FOR...

Resonance Health Ltd on 6ix

In the deck

Earlier from Resonance Health

Later from Resonance Health

All Resonance Health news releases